Q32 Bio Advances in Atopic Dermatitis Treatment Trial
Company Announcements

Q32 Bio Advances in Atopic Dermatitis Treatment Trial

Q32 Bio (QTTB) has issued an announcement.

Q32 Bio Inc. has successfully completed the enrollment phase for the SIGNAL-AD Phase 2 clinical trial of their drug bempikibart, aimed at treating persistent, moderate-to-severe atopic dermatitis. The trial explores the efficacy of bempikibart, an antibody that blocks inflammatory signaling with the hope of re-regulating immune function. With 121 patients enrolled, surpassing the initial goal due to high demand, the study’s findings are eagerly anticipated in the fourth quarter of 2024. This milestone marks a significant step for Q32 Bio Inc. as they advance in the development of potential new treatments for autoimmune disorders.

For a thorough assessment of QTTB stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyQ32 Bio initiated with a Strong Buy at Raymond James
TipRanks Auto-Generated NewsdeskQ32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
TheFlyQ32 Bio initiated with an Overweight at Wells Fargo
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App